One-Year COMBO Stent Outcomes in Acute Coronary Syndrome: from the COMBO Collaboration
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07087-6
Abstract: The COMBO biodegradable polymer sirolimus-eluting stent includes endothelial progenitor cell capture (EPC) technology for rapid endothelialization, which may offer advantage in acute coronary syndromes (ACS). We sought to analyze the performance of the COMBO stent… read more here.
Keywords: stemi; combo stent; acs; year ... See more keywords
Obtaining turbulence statistics of thermally driven anabatic flow by sonic-hot-film combo anemometer
Sign Up to like & getrecommendations! Published in 2018 at "Environmental Fluid Mechanics"
DOI: 10.1007/s10652-018-9649-x
Abstract: Achieving a better understanding of atmospheric boundary layer flows, and of slope flows in particular, is of paramount importance for the research of climate processes and production of accurate weather forecasts. We addressed the need… read more here.
Keywords: thermally driven; driven anabatic; turbulence; turbulence statistics ... See more keywords
MO624COMBINATION TREATMENT WITH LISINOPRIL AND EMPAGLIFLOZIN IMPROVES BIOCHEMICAL AND HISTOLOGICAL MARKERS OF DIABETIC NEPHROPATHY IN HYPERTENSIVE UNINEPHRECTOMIZED DB/DB MICE
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab093.005
Abstract: Emerging treatments of diabetic kidney disease (DKD) include SGLT2 inhibitors and GLP-1 receptor agonists that are nephroprotective beyond their blood glucose lowering effects. Despite this progress, patients with diabetes are still at risk of developing… read more here.
Keywords: vehicle; combo; mice; treatment ... See more keywords
Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4519
Abstract: 4519 Background: INDUCE-1 is a first-in-human trial evaluating fela, an IgG4 ICOS agonist non-T-cell depleting mAb, as monotherapy (mono) and in combo with P. ECs include tumor types, such as UC, with high ICOS expression… read more here.
Keywords: combo; fela; activity; disease ... See more keywords